Literature DB >> 12639822

Enhanced proliferation of functionally competent bone marrow cells in different strains of mice treated with swainsonine.

Oladipo A Oredipe1, Paulette M Furbert-Harris, Ibrahim Laniyan, William R Green, Sandra L White, Kenneth Olden, Debra Parish-Gause, Theresa Vaughn, Walter M Griffin, Rajagopalan Sridhar.   

Abstract

The immunomodulatory alkaloid swainsonine (8alphabeta-indolizidine-1alpha,2alpha,8beta-triol) has potential for overcoming the bone marrow suppressive effects of cancer chemotherapy and radiotherapy. An earlier study showed that multiple doses of swainsonine enhanced bone marrow cellularity in four different strains (C57BL/6; C3H-HEN; Balb/C and DBA-2 mice) of inbred mice which were not exposed to any chemotherapeutic agents or radiation. In vitro assessment of total colony formation capacity of bone marrow cells (BM CFUs) showed a 2- to 8-fold increase in swainsonine-treated mice compared to control mice that were given sham injections of physiological saline. In the current study, we have evaluated the functional competence of the bone marrow cells produced in response to swainsonine treatment of normal healthy mice. In particular, colony forming units-granulocyte-macrophage (CFU-GM), erythroid-burst forming units (BFUe) and CFU-Mix (or CFU-granulocyte-erythrocyte-monocyte-megakaryocyte (CFU-GEMM)) levels, were determined using in vitro assays. The time course of the changes in CFU-GM, BFUe and CFU-Mix (CFU-GEMM) were also followed. Our results demonstrate that swainsonine bolsters the CFU capacity of BM cells without loss of function to levels which are several folds higher than in sham-treated control mice. Swainsonine treatment caused an increase in all lineages of marrow cells without loss of function. This effect was reproduced in all four strains of inbred mice in this investigation. Examination of the peripheral blood did not reveal increase in white blood cells or changes in the hematocrit levels. The long-term effects of swainsonine treatment are not known at present. Nonetheless, swainsonine-induced increase in CFU capacity of bone marrow cells and related cells along the different differentiation paths should find clinical application in cancer treatment with chemotherapeutic agents and/or radiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639822     DOI: 10.1016/S1567-5769(03)00042-0

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  1 in total

1.  Swainsonine activates mitochondria-mediated apoptotic pathway in human lung cancer A549 cells and retards the growth of lung cancer xenografts.

Authors:  Zhaocai Li; Xingang Xu; Yong Huang; Li Ding; Zhisheng Wang; Gaoshui Yu; Dan Xu; Wei Li; Dewen Tong
Journal:  Int J Biol Sci       Date:  2012-02-24       Impact factor: 6.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.